RegeneRx Biopharmaceuticals, Inc. is addressing rumors in the market regarding its ARISE-3 phase 3 dry eye trial. Based on current communication with GtreeBNT, the company's partner in the 700-patient ARISE-3 clinical trial, the patient database is continuing to be cleaned prior to its being locked. This is talking a little longer than expected but should be completed very soon. The patient database will then be locked, and the trial data analyzed shortly thereafter followed by the release of top line results,' stated J.J. Finkelstein, RegeneRx president and chief executive.